Eli Lilly and Company (NYSE: LLY) said its investigational drug retatrutide delivered “more than double the weight loss of the highest approved dose of Ozempic,” from Novo Nordisk A/S (NYS[...]
By using this site, you agree to the storage of cookies on your device for enhanced navigation, site analysis, and The TradingPub's marketing. Data sharing with social media platforms might occur based on the privacy choices you make on those platforms. For specifics, see our Privacy Policy.
